We want to start a new trial on stroke recovery and the clinicians involved are not used to administer the Fugl-Meyer. How to prevent learning effects to maximize intra-rater reliability and external validity? I wonder how do other labs and hospitals deal with this issue. Are there any official common guidelines on this?

Similar questions and discussions